4G/5G polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene in subjects with node-negative and node-positive breast cancer
Beata Smolarz, Janusz Błasiak, Jacek Pytel, Hanna Romanowicz-Makowska, Marek ZadrożnyMed Sci Monit 1999; 5(5): BR833-837 :: ID: 503262
Abstract
PAI-1 is a serine protease inhibitor involved in the degradation of the extracellular matrix during malignant tumor invasion and its high level in breast cancer is associated with a poor prognosis for patients. It is supposed that 4G/5G insertion/deletion polymorphism, with a sequence of either four guanosines or five guanosines, in the promoter of the PAI-1 gene may play a functional role in PAI-1 synthesis, affecting the level of circulating PAI-1. To investigate whether the progression of breast cancer may be related to a particular genotype, 4G/5G polymorphism in patients with node-negative (n=17) and node-positive (n=20) breast cancer was studied. The subjects were 44 to 82 years old, with a median age of 59 years. Formalin-fixed, paraffin-embedded material from ductal breast carcinoma was used. The tumors' diameter was about 20 mm and they were classified of II, II°, III or III°grade. The 4G/5G polymorphism of PAI-1 gene was determined by the allele specific polymerase chain reaction (ASO-PCR). The genotype distribution differed significantly between node-negative and node-positive groups. The 4G allele was observed more frequently in node-negative patients (0.74) compared with 5G allele (0.26), whereas in subjects with node-positive the frequency 4G and 5G allele were 0.48 and 0.52, respectively. Different distribution of the 4G/5G genotypes in patients indicate that this genetic variation itself may be a risk factor for breast cancer invasive phenotype, so the association of the 4G/5G polymorphism with breast cancer progression is worth further studying.
Keywords: PAI-1 - plasminogen activator inhibitor-1, 4G/5G polymorphism, prognostic factor, node-negative and node-positive breast cancer, allele specific polymerase chain reaction (ASO-PCR)
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952